TY - JOUR
T1 - Peptido-targeting of the mitochondrial transition pore complex for therapeutic apoptosis induction
AU - Deniaud, Aurélien
AU - Hoebeke, Johan
AU - Briand, Jean Paul
AU - Muller, Sylviane
AU - Jacotot, Etienne
AU - Brenner, Catherine
PY - 2006/12/1
Y1 - 2006/12/1
N2 - The permeability transition pore (PTPC), a polyprotein complex, participates in the mitochondrial homeostasis as well as in the mitochondrial phase of the intrinsic pathway of apoptosis. It integrates multiple death signals including alterations of the intracellular milieu, translocation of pro-apoptotic members of the Bax/Bcl-2 family, p53, and viral proteins. As a consequence, PTPC can act as a coordinator of the pro-apoptotic mitochondrial membrane permeabilization process and the release of pro-apoptotic intermembrane space proteins into the cytosol. Moreover, the deregulation PTPC has been involved in several major human pathologies such as cancer, neurodegeneration, ischemia/ reperfusion, aging, as well as hepatotoxicity. Therefore, PTPC has emerged as a promising potential therapeutic target. Here, we will review the current knowledge concerning the two opposite functions of the PTPC and its implication in various pathologies. We will discuss the possibility to target this complex with peptides to modulate apoptosis in an innovative therapeutic perspective.
AB - The permeability transition pore (PTPC), a polyprotein complex, participates in the mitochondrial homeostasis as well as in the mitochondrial phase of the intrinsic pathway of apoptosis. It integrates multiple death signals including alterations of the intracellular milieu, translocation of pro-apoptotic members of the Bax/Bcl-2 family, p53, and viral proteins. As a consequence, PTPC can act as a coordinator of the pro-apoptotic mitochondrial membrane permeabilization process and the release of pro-apoptotic intermembrane space proteins into the cytosol. Moreover, the deregulation PTPC has been involved in several major human pathologies such as cancer, neurodegeneration, ischemia/ reperfusion, aging, as well as hepatotoxicity. Therefore, PTPC has emerged as a promising potential therapeutic target. Here, we will review the current knowledge concerning the two opposite functions of the PTPC and its implication in various pathologies. We will discuss the possibility to target this complex with peptides to modulate apoptosis in an innovative therapeutic perspective.
KW - ATP cell content
KW - Cancer
KW - Inner mitochondrial membrane (IM)
KW - Ischemic reperfusion injury
KW - Voltage-dependent anion channel (VDAC)
UR - http://www.scopus.com/inward/record.url?scp=33751543499&partnerID=8YFLogxK
U2 - 10.2174/138161206779010530
DO - 10.2174/138161206779010530
M3 - Review article
C2 - 17168756
AN - SCOPUS:33751543499
SN - 1381-6128
VL - 12
SP - 4501
EP - 4511
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 34
ER -